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Abstract 
An 80-year-old woman was admitted to our hospital with pneumonia and exacerbation of 
sinobronchial syndrome (SBS). She presented with yellow discoloration of the nail beds of all 
fingers and toes, and her nails were recognized as growing slowly. Chest X-ray revealed 
bronchiectasis in the bilateral lower lobe and bilateral pleural effusion. We diagnosed her as 
having yellow nail syndrome (YNS), based on the triad of yellow nails, lymphedema, and lung 
disease. After treatment with antibiotics [ampicillin/sulbactam and clarithromycin (CAM)] for 
pneumonia and SBS, her general condition improved, and the yellow nails disappeared in 
some fingers. When she was previously treated with 200 mg CAM for SBS, her yellow nails 
had not shown improvement. This time, her yellow nails improved after treatment with 400 
mg CAM. The literature reports vitamin E, zinc, and topical corticosteroid plus active vitamin 
D3 to be effective in the treatment of yellow nails. Two studies have reported treatment for 
YNS using CAM, though they found a lack of efficacy. Thus, the present case is the first to 
report improved yellow nails using CAM alone. We conclude that not only SBS and lung 
disease but also YNS were improved by treatment with 400 mg CAM. 
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Introduction 
Yellow nail syndrome (YNS) is a rare disorder of unknown cause characterized by 
the triad of yellow discoloration and thickened nails with slow growth, chronic 
lymphedema, and respiratory manifestations, such as bronchiectasis or pleural effusion 
[1, 2]. We examined a patient with YNS and underlying sinusitis, who suffered from 
slow growth and yellow discoloration of the nails, bronchiectasis, bilateral pleural 
effusion, and peripheral lymphedema. Based on the presence of the three basic 
symptoms, the patient was diagnosed as having YNS. We report the efficacy of 
clarithromycin (CAM) for treating yellow nails: only 400 mg per day dramatically 
improved the yellow nail discoloration and growth of nails in this patient. 
Case Report 
An 80-year-old woman was admitted to our hospital because of pneumonia. Her symptoms were 
loss of appetite, pyrexia, and purulent sputum, which had worsened despite CAM treatment of 200 mg 
per day. The underlying diseases were a colon polyp, sinusitis, and Candida onychomycosis infection. 
On physical examination, her height was 145 cm, her weight 35 kg, blood pressure 108/60 mm Hg, 
pulse rate 70 beats/min and regular, body temperature 36.6°C, and respiratory rate 21 per minute. 
The patient was lucid, and she did not suffer from anemia or icterus; the superficial lymph nodes were 
not swollen. On auscultation, the breath sounds revealed a coarse crackle in the bilateral lower fields. 
The abdomen was soft and flat. Neurological examination results were normal. There was a slight 
peripheral pitting edema at the ankle joints. Bilaterally, the nails of the fingers and toes were of a 
yellow-green color; there were thickness of the beds, onycholysis, and slow growth, as a result of 
which she had not cut her nails for over 6 months. The blood test showed an increasing inflammatory 
reaction and slight hypoxia (table 1). Urinary findings, renal function, and brain natriuretic peptide 
values were normal. Deep mycosis was also considered because of her nail discoloration, but beta-D-
glucan and candida antigen tests were negative. The initial X-ray revealed infiltration in the bilateral 
lower fields, in particular a lack of cardiac silhouette over a part of the left diaphragm, ‘tramline’ 
shadows as a clinical feature of bronchiectasis, and blunting of the bilateral costophrenic angles 
(fig. 1). 
The patient was diagnosed as having YNS because her nails had previously been resistant to 
therapy for nail candidiasis and she had lung complications. After admission, she was treated with 
4.5 g per day of sulbactam/ampicillin for pneumonia and 400 mg per day of CAM for exacerbation of 
sinobronchial syndrome (SBS). Since her respiratory tract symptoms and inflammatory changes were 
showing improvement after 10 days of treatment, the nail discoloration and slow growth were 
recognized as having been ameliorated by this treatment. 
The patient had previously been diagnosed with nail candidiasis, but the nails did not improve 
despite mycosis treatment. Fig. 2 shows the clinical course of treatment. Since 2001, the patient has 
been treated with a topical antifungal cream for her nails. Since 2002, she has also received 200 mg 
CAM per day as SBS treatment. Though CAM treatment was discontinued following an improvement 
in the patient’s lung complaints, the nail lesions were unaffected. Subsequently, the nail improvement 
was achieved following treatment with 400 mg CAM daily. 
Photographs of the nails before and after treatment are shown in fig. 3. After the treatment, the 
yellow-green areas of the nails had decreased at the nail matrix, and at the nail matrix new nail 
growth was found. In particular, the small finger showed great improvement in nail discoloration and 
slow growth; subsequently, her nails required cutting. The patient was administered only with 
intravenous antibiotics and oral macrolide. We consider that CAM treatment was more effective for 
YNS. 
The patient continues to receive outpatient treatment of 400 mg CAM per day, and the condition of 
her nails is improving.  
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Discussion 
YNS is a rare disorder of unknown cause characterized by the classic triad of yellow 
and thickened nails, lymphedema, and respiratory manifestations. In 1964, Samman 
and White [1] described YNS in 13 cases. Typically, the nails grow slowly, are 
excessively curved, and show a yellow discoloration. They frequently show ridging 
owing to interrupted growth. Onycholysis can occur in one or more nails. On the other 
hand, in 1966 Emerson [2] described 3 patients with yellow discoloration of the nails, 
pleural effusion, and chronic lymphedema as representing a new syndrome. The 
patient in the present study had slow-growing and yellow nails, lymphedema, and 
respiratory manifestation, and she was confirmed to have YNS. 
According to an analysis of 97 YNS patients reported by Nordkild et al. [3], 89% had 
yellow nails, 80% had lymphedema, and 36% had lung disease. Of 50 cases reported by 
Mambretti-Zumwalt et al. [4], only 13 (27%) had the complete triad of symptoms. 
Though visible change in the peripheral edema did not appear in the present case, 
yellow nails and bronchiectasis with pleural effusion led to the diagnosis of YNS. 
In the differential diagnosis, nail inspection takes into account focal infections, such 
as nail candidiasis and tinea unguium. Such cases can be confirmed by mycological 
examination based on fungal cultures of the nails or microscopic visualization of the 
fungal forms. Changes in the condition of the nails and response to therapy vary with 
time. In a refractory case where all finger- or toenails are discolored and recognized as 
being associated with respiratory disease, the diagnosis should be YNS. 
The cause of YNS is unknown. It has been suggested as being a congenital lymph 
abnormality, though one in which the disorder is very mild. In addition to skin or 
respiratory infection, any stress, such as trauma, after growth leads to obvious 
lymphatic drainage abnormalities and results in lymphedema. These changes produce 
an overall rate of growth that is usually less than one tenth that of normal [1]. The nail 
grows more slowly than 0.2 mm/week compared with the minimum of 0.5–1.2 
mm/week in healthy subjects. Because of the slow growth, the nails’ color ranges from 
pale yellow or slightly greenish to shades of black, and the nails are thickened and 
usually excessively curved from side to side; onycholysis, disappearance of the lunulae, 
deficient cuticles, paronychia, and transversal grooves may be present [2]. 
The bronchiectasis that accompanies YNS often coexists with chronic sinusitis. 
Chronic sinusitis has been reported in 20–25% cases of YNS [5]. The cause of 
bronchiectasis is also unknown, but it has been hypothesized that bronchiectasis may 
be induced by sinobronchial lymph duct occlusion [3]. Bronchial mucosa biopsy has 
demonstrated that edematous changes are associated with lymphatic congestion [6]. 
Therefore, we hypothesize that a recurrent respiratory tract infection caused by 
lymphatic congestion leads to a locally acquired immunocompromised state and 
bronchiectasis. 
Vitamin E [7], zinc [8], and topical corticosteroid plus active vitamin D3 [3] have 
been reported to be effective for treating yellow nails. Two cases of treating YNS with 
CAM have been described. In one case of complicated SBS, respiratory disease and nail 
discoloration showed improvement following treatment with CAM and topical 
corticosteroid [5]. In the other case of complicated SBS associated with eosinophilic  
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bronchial disease, the respiratory disease evidenced improvement, though the nail 
discoloration failed to improve following treatment with CAM and budesonide [9]. 
We will now consider the mechanisms whereby the nail disease improved following 
amelioration of the respiratory disease. It has been noted that 14-membered macrolide 
antibiotics, including CAM, have various anti-inflammatory effects in addition to the 
antibacterial effects. They inhibit water and mucus secretion by the tracheal 
epithelium, chloride secretion across canine tracheal epithelial cells [10], and MUC5AC 
production [11]. These antibiotics also inhibit inflammatory cytokines and the anti-
proliferative effect of inflammatory cells, such as decreasing secretion of IL-6 and GM-
CSF from epithelial cells, inhibiting IL-2, -3, and -4 production from lymphocytes, and 
decreasing the production of IL-1, TNFα, and IL-8 from monocytes and macrophages 
[12]. In our patient, the nail improvement appeared to be associated with better control 
of the respiratory manifestations following treatment of SBS with CAM. In fact, several 
authors have reported some improvement in the nail abnormalities following better 
control of the respiratory manifestations or decongestive therapy for lymphedema. We 
examined the relationship between dose and effect of CAM in our patient. When she 
was treated with 200 mg CAM for SBS in 2002, there was no improvement in her yellow 
nails. At that time, improvement in the nail coloration occurred after treatment with an 
increased dose of 400 mg CAM. Ianaro et al. [13] reported the anti-inflammatory 
activity of macrolide antibiotics. In the present study, we described how both the 
exudate volume and leukocyte accumulation were dose-dependently reduced by CAM. 
Furthermore, the production of IL-1β, TNF-α, and IL-6 were also reportedly reduced by 
macrolides [13]. A dose of over 400 mg CAM has the potential to improve the nail 
discoloration in YNS. 
The literature reports no evidence of nail improvement in YNS using CAM alone. 
Thus, the present case is the first report of such yellow nail improvement using only 
CAM. Treatment with over 400 mg CAM for YNS accompanied with sinusitis may 
improve not only the sinusitis and lung disease but also the yellow nails associated with 
lymphedema of the periungual tissue. 
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Table 1. Laboratory data on admission 
Hematology    Serology    Immune serum    Atrial blood gas 
WBC  10,560/μl    Alb  2.8 g/dl    β-D glucan  6.6 pg/ml    pH  7.369 
Neu  87.6%    AST  43 U/l    BNP  5.9 pg/ml    PCO2  38.3 mm Hg 
Lym  8.3%    ALT  28 U/l    IgG  1,744.7 pg/dl    PO2  69.5 mm Hg 
Mon  4.2%    LDH  211 U/l    IgA  169.8 pg/dl    HCO3  23.5 mmol/l 
Eos  0.1%    γGTP  23 U/l    IgM  46.3 pg/dl       
Bas  0.1%    BUN  13.8 mg/dl    T-IgE  15.0 U/ml       
RBC  399×104/μl    Cre  0.52 mg/dl             
Ht  33.1%    Na  135 mEq/l             
Hb  10.0 g/dl    K  3.6 mEq/l             
Plt  28.4×104/μl   Cl  99 mEq/l             
      CRP  18.01 mg/dl            
WBC = White blood cell; Neu = neutrophil; Lym = lymphocyte; Mon = monocyte; Eos = eo-sinophil; Bas = 
basophil; RBC = red blood cell; Hb = hemoglobin; Ht = hematocrit; Plt = platelet; Alb = albumin; AST = 
aspartate aminotransferase; ALT = alanine aminotransferase; LDH = lactate dehydrogenase; γGTP = γ 
glutamyl transpeptidase; BUN = blood urea nitrogen; Cr = creatinine; Na = sodium; K = potassium; Cl = 
chloride; CRP = C-reactive protein; BNP = brain natriuretic peptide; IgG = immunoglobulin G; IgA = 
immunoglobulin A; IgM = immunoglobulin M; T-IgE = total immunoglobulin E; HCO3 = bicarbonate ion; 
PCO2 = partial pressure of arterial carbon dioxide; PO2 = partial pressure of arterial oxygen. 
 
 
 
 
 
Fig. 1. Chest X-ray on admission showed bilateral lower lobe infiltration. ‘Tramline’ revealed in the 
right lower lobe. 
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Fig. 2. Clinical history of the patient with regard to nail discoloration and sinobronchial syndrome 
(SBS). 
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Fig. 3. The yellow nails improved dramatically after 9 months of CAM treatment. a Pretreatment. 
b Posttreatment. 
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